This week in regulatory: 45 updates, +165% vs last week

The top regulatory developments of the week, ranked by significance

Taken together, these updates may indicate a sharper regulatory emphasis on lifecycle discipline, with FDA enforcement transparency, MHRA packaging quality failures, and WHO digital process standardization all pointing toward tighter expectations for traceability and timely remediation. Pharmaceutical companies should consider strengthening cross-functional readiness around inspection response, artwork and supply-chain controls, and digital submission workflows, as these developments could suggest that weak document control or product information mismatches are increasingly visible to regulators. RA, clinical ops, and QA professionals should prioritize alignment on evidence readiness, defect escalation pathways, and system preparedness for mandatory ePQS use, since coordinated execution may be the difference between routine compliance and avoidable regulatory friction.